List of Excipients in Branded Drug BREVIBLOC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	BREVIBLOC	esmolol hydrochloride	10019-115	ACETIC ACID
Baxter Healthcare Corporation	BREVIBLOC	esmolol hydrochloride	10019-115	HYDROCHLORIC ACID
Baxter Healthcare Corporation	BREVIBLOC	esmolol hydrochloride	10019-115	SODIUM ACETATE
Baxter Healthcare Corporation	BREVIBLOC	esmolol hydrochloride	10019-115	SODIUM CHLORIDE
Baxter Healthcare Corporation	BREVIBLOC	esmolol hydrochloride	10019-115	SODIUM HYDROXIDE
Baxter Healthcare Corporation	BREVIBLOC	esmolol hydrochloride	10019-115	WATER

Brevibloc Excipient Strategy and Commercial Opportunities for Esmolol Hydrochloride

Last updated: August 24, 2026

Brevibloc is an injectable esmolol hydrochloride product used for short-term control of supraventricular tachycardia and rapid ventricular rate, and for perioperative tachycardia or hypertension. Its commercial opportunity is no longer based on primary-molecule exclusivity. It is based on ready-to-use delivery, stability, container compatibility, waste reduction, emergency-department workflow, pediatric dosing, and differentiated hospital supply economics.

The strongest product concepts are preservative-free, ready-to-administer esmolol presentations with validated in-use stability and low preparation requirements. Excipient selection should prioritize chemical stability, injection compatibility, osmolality, particulate control, and container closure performance over novel excipient claims.

What is Brevibloc and what excipients does it contain?

Brevibloc contains esmolol hydrochloride, an ultrashort-acting beta-1 adrenergic blocker administered by intravenous infusion. The product’s rapid metabolism by red-blood-cell esterases gives it a short duration of action and supports titratable hospital use.[1]

Commercial esmolol products are supplied in multiple concentrations and formats, including premixed infusion bags, ready-to-use vials, and concentrated vials requiring dilution. The exact inactive-ingredient profile depends on the presentation and manufacturer.

Product characteristic	Commercial relevance
Active ingredient	Esmolol hydrochloride
Route	Intravenous infusion
Typical use setting	Operating room, intensive care, emergency department, cardiac care
Common dosage form	Sterile aqueous solution
Common concentrations	10 mg/mL, 20 mg/mL, and concentrated presentations
Typical excipient system	Water for injection, sodium chloride or acetate-based buffering, pH adjusters
Preservative strategy	Generally preservative-free single-dose products
Primary formulation risk	Hydrolysis, pH drift, container interaction, dilution and in-use compatibility
Primary commercial differentiator	Ready-to-use delivery and reduction of pharmacy preparation

Brevibloc labeling identifies formulation-specific inactive ingredients and storage requirements. Product developers should treat the approved label, current DailyMed entry, and the applicable reference-product record as controlling for any formulation comparison.[1,2]

Which excipients are most important for esmolol hydrochloride formulation?

The core excipient strategy is a controlled aqueous buffer system with low particulate risk and acceptable physiological tolerability.

Water for injection

Water for injection is the principal vehicle. It must support sterile manufacture, low endotoxin levels, and reliable assay performance during the labeled shelf life. Because esmolol is administered intravenously, excipient load and osmolality are commercially important. High excipient concentrations can create infusion-site concerns and may reduce flexibility for peripheral administration.

Sodium chloride

Sodium chloride can provide isotonicity in premixed products. A sodium-chloride-based presentation aligns with hospital expectations for standard infusion fluids and simplifies direct connection to infusion systems.

Its limitations are also commercially relevant. A sodium-chloride platform adds sodium load and may limit opportunities to position a product for patients in whom fluid or electrolyte exposure is tightly managed. It can also create a less differentiated product if competing generic manufacturers already offer comparable saline premixes.

Sodium acetate and acetic acid

Acetate-based systems can provide pH control while avoiding reliance on phosphate or other buffers that may have compatibility limitations. The reference product’s formulation history and current labeling should guide the acceptable concentration range.

Acetate systems require assessment of:

• pH drift during storage and infusion;
• compatibility with elastomeric closures and tubing;
• extractables and leachables;
• precipitation after dilution;
• osmolality at the finished-product concentration;
• degradation under heat and light stress.

Hydrochloric acid and sodium hydroxide

These materials are generally used as pH adjusters rather than as principal formulation excipients. Their commercial importance is process control. Small pH changes can affect degradation, impurity formation, and compatibility with the container closure system.

A development program should establish a justified pH target rather than simply matching a competitor’s nominal value. The target should be linked to degradation kinetics, visible and subvisible particles, sterility assurance, and infusion compatibility.

Preservative-free design

Preservative-free packaging is preferable for an intravenous beta blocker used in acute care. It reduces concerns about preservative exposure and supports single-dose labeling. Multidose presentations may create a limited cost advantage but introduce additional antimicrobial-preservation, administration, and regulatory complexity.

What formulation patents protect Brevloc and generic esmolol products?

Primary patent protection for esmolol hydrochloride and the original Brevibloc product has expired. The commercial barrier is therefore regulatory execution and hospital contracting rather than active-molecule patent exclusivity.

The original esmolol intellectual-property estate included composition and pharmaceutical-use protection associated with the molecule and its beta-blocking activity. Those rights are historical and do not create a current U.S. exclusivity position comparable to a newly launched branded drug.

IP category	Current strategic assessment
Esmolol composition of matter	Historical protection; expired
Original Brevibloc product protection	Historical protection; expired
New-molecule exclusivity	Expired
U.S. Orange Book patent barrier	No practical current barrier expected for routine esmolol injection development
Formulation patents	Possible only for genuinely differentiated systems, packaging, or stability performance
Method-of-use patents	Limited commercial value where the use is established and generic labeling is broad
Manufacturing patents	Potential value for high-concentration solutions, impurity control, sterile filling, or improved shelf life
Trade secrets	Potentially important for container compatibility, process controls, and extractables data

An applicant should distinguish between a patentable formulation and a formulation that merely uses known excipients at routine concentrations. A claim covering esmolol, water, sodium chloride, and a conventional pH adjuster would face substantial obviousness and enablement risk unless supported by an unexpected stability, compatibility, or manufacturing result.

How strong is the patent estate for Brevibloc?

The patent estate is weak as a barrier to generic entry and potentially useful only as a freedom-to-operate reference point. The economic value lies in formulation execution, not exclusionary rights.

A defensible follow-on patent could focus on:

1. A concentrated esmolol solution with improved chemical stability.
2. A low-volume formulation that avoids dilution before administration.
3. A defined buffer range that reduces a specific impurity.
4. A container closure system that limits adsorption or leachables.
5. A ready-to-use product with extended in-use stability.
6. A specific high-concentration presentation for controlled infusion devices.
7. A manufacturing process that reduces degradation products at commercial scale.

The evidence threshold is high. A patent strategy should include comparative data against the reference product and other commercially relevant formulations. Stability at accelerated and long-term conditions, dilution studies, infusion-device compatibility, and extractables and leachables data are more valuable than broad excipient lists.

What FDA regulatory status applies to Brevibloc and generic esmolol?

Brevibloc was approved as an NDA product, and generic esmolol hydrochloride injections can generally be developed through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[3]

Regulatory issue	Implication
Reference product	Brevibloc or the FDA-designated reference product
Likely generic pathway	ANDA under section 505(j)
Clinical efficacy requirement	Usually supported by reference-product reliance rather than a new efficacy trial
Key CMC burden	Sterility, assay, impurities, particulate matter, pH, osmolality, container closure, stability
Bioequivalence focus	Injectable products may qualify for waiver or simplified demonstration depending on formulation and route
Labeling	Must generally be the same as, or appropriately linked to, the reference labeling
Exclusivity	Original regulatory exclusivity has expired
Orange Book relevance	Check current patent and exclusivity listings for the selected reference product before filing

A materially different excipient system, novel concentration, new container configuration, or new dosing presentation may create 505(b)(2) considerations rather than a straightforward ANDA pathway. The regulatory classification depends on whether the proposed product can meet the sameness and labeling requirements for an ANDA.

FDA guidance places particular importance on injectable-product quality attributes, including particulate matter, sterility, endotoxins, extractables and leachables, and container closure integrity.[4,5]

What formulation opportunities exist for esmolol hydrochloride?

Ready-to-use infusion bags

Ready-to-use bags are the most commercially credible opportunity. They reduce pharmacy compounding, preparation time, dose-calculation errors, and sterile manipulation. Hospitals may value a product that can be removed from inventory and connected directly to an infusion pump.

A differentiated portfolio could include:

Presentation	Commercial rationale
10 mg/mL premixed bag	Standardized infusion for high-volume hospital use
20 mg/mL ready-to-use vial	Lower preparation volume and flexible pump setup
Higher-concentration vial	Useful where fluid restriction or prolonged infusion is important
Small-volume vial	Supports procedural and emergency use
Pharmacy bulk or institutional presentation	May reduce unit cost but increases regulatory and handling complexity
PVC-free bag	Addresses institutional material policies and compatibility concerns
DEHP-free system	Supports procurement requirements in hospitals and pediatric settings

The product should be evaluated with common infusion pumps, administration sets, filters, and tubing materials. A theoretically stable solution can still fail commercially if it requires special equipment or produces unacceptable adsorption, leachables, or pump alarms.

Low-volume and concentrated products

Concentrated esmolol can reduce fluid burden and simplify administration in intensive-care settings. The trade-off is greater risk of dosing error and the need for dilution instructions. A concentrated product has the strongest value proposition where fluid restriction, high-dose infusion, or limited IV access is common.

Commercial success would depend on clear differentiation from standard 10 mg/mL products. Labeling, barcode configuration, pharmacy protocols, and smart-pump library integration are as important as the concentration itself.

Pediatric and neonatal presentations

Pediatric and neonatal use creates a potential niche for low-volume, preservative-free products. The opportunity is operational rather than based on a new mechanism. Relevant design requirements include:

• small container fill volume;
• low dead-space administration;
• accurate withdrawal from the container;
• compatibility with syringe pumps;
• clear concentration labeling;
• minimized preparation steps;
• robust stability after first puncture or transfer, if permitted by labeling.

Any pediatric positioning would require appropriate regulatory support and should not rely solely on adult labeling assumptions.

Closed-system and pharmacy workflow products

A ready-to-use syringe or closed-transfer-compatible presentation could improve emergency response and reduce manipulation. The commercial opportunity is strongest where hospitals have centralized pharmacy compounding, high procedural volume, or strict hazardous-drug-style workflow controls, even though esmolol itself is not generally managed as a hazardous drug.

What manufacturing and IP barriers affect esmolol formulation?

The main manufacturing barriers are product quality and scale-up consistency.

Chemical stability

The development program should monitor assay, related substances, pH, color, visible particles, subvisible particles, and container closure integrity. Esmolol contains an ester group associated with rapid enzymatic metabolism, and the finished product still requires chemical stability control during manufacture and storage.

Risk factors include:

• elevated temperature;
• prolonged exposure to extreme pH;
• oxygen exposure;
• repeated temperature cycling;
• interaction with elastomeric components;
• excessive hold times before filling;
• dilution into nonvalidated solutions.

Container closure compatibility

A commercial formulation must be tested in the proposed vial, bag, syringe, stopper, port, overwrap, and administration set. Materials may differ in adsorption, permeability, extractables, and leachables.

Polyolefin and multilayer bag systems may offer commercial differentiation over conventional PVC, but the benefit must be supported by procurement demand and compatibility data. Packaging changes can also trigger supplemental regulatory work and new stability commitments.

Sterile manufacturing

Esmolol products are sterile injectables, so manufacturing economics are heavily affected by aseptic processing, filling-line capacity, environmental monitoring, container closure integrity, and reject rates. A product with modest ingredient cost can still have high cost of goods if its packaging format is inefficient or its fill-volume tolerance is narrow.

Which companies are challenging Brevibloc in the commercial market?

Competition comes primarily from generic injectable manufacturers and hospital-supply companies rather than from biosimilar developers. Esmolol is a small molecule, so biosimilar regulation does not apply.

The competitive field typically includes:

• branded Brevibloc or successor commercial rights holders;
• generic injectable manufacturers;
• contract manufacturing organizations;
• hospital-focused premix suppliers;
• specialty injectable companies offering concentrated or ready-to-use presentations.

Competitive advantage is likely to come from supply reliability, national shortage performance, contract pricing, 503B pharmacy relationships where applicable, and ready-to-use packaging. A low-price vial without a meaningful workflow benefit is exposed to rapid commoditization.

What generic entry risks exist for Brevibloc?

Generic entry risk is high because:

• the active ingredient is old and well characterized;
• primary exclusivity has expired;
• injectable generic development can rely on established clinical use;
• hospitals often use therapeutic interchange and formulary substitution;
• the formulation platform is technically familiar;
• several concentration and packaging approaches are feasible.

The remaining risks are execution risks:

1. Failure to match reference-product quality attributes.
2. Stability failures after scale-up.
3. Container or tubing incompatibility.
4. FDA complete-response-letter risk.
5. Supply interruptions after launch.
6. Limited access to hospital contracts.
7. Pricing erosion from multiple generic suppliers.
8. Confusion between concentrated and ready-to-use products.

A branded follow-on product can reduce price competition only if it produces a clear operational benefit, such as eliminating dilution, reducing fluid volume, improving pump compatibility, or offering superior supply continuity.

How does Brevibloc compare with competing short-acting beta blockers?

Product	Active ingredient	Primary advantage	Excipient and packaging opportunity
Brevibloc	Esmolol hydrochloride	Very short, titratable beta-1 blockade	Ready-to-use, concentrated, low-volume, and device-compatible presentations
Landiolol products	Landiolol hydrochloride	Short-acting beta-1 blockade in selected markets	Regional regulatory and market-access opportunity
Labetalol injection	Labetalol hydrochloride	Combined alpha- and beta-blockade	Different clinical positioning; less direct formulation substitution
Metoprolol injection	Metoprolol tartrate	Familiar hospital beta blocker	Longer-acting profile and less titratable infusion positioning

Esmolol’s strongest commercial distinction is controllability. The formulation should preserve that advantage by enabling precise infusion, rapid preparation, and predictable delivery.

What licensing deals and commercial partnerships are relevant?

No active-molecule licensing opportunity is required to commercialize a conventional esmolol generic. The more relevant transactions are:

• regional licensing of approved injectable products;
• contract manufacturing and fill-finish agreements;
• hospital-premix distribution partnerships;
• exclusive supply agreements with group purchasing organizations;
• co-development of device-compatible presentations;
• acquisition or licensing of container and administration-system technology.

A licensing target should be assessed for FDA approval status, manufacturing redundancy, shortage history, ANDA ownership, product-specific litigation, and rights to packaging configurations. For esmolol, manufacturing access and hospital distribution are likely to have greater value than broad patent rights.

What revenue exposure and market opportunities exist?

Brevibloc revenue is exposed to generic substitution and hospital purchasing pressure. The addressable opportunity is concentrated in acute-care institutions rather than retail pharmacy.

The most attractive segments are:

• operating rooms requiring rapid perioperative heart-rate control;
• intensive-care units with titratable hemodynamic management;
• emergency departments;
• cardiac catheterization and electrophysiology laboratories;
• pediatric and neonatal intensive-care units;
• hospitals seeking premixed products because of pharmacy labor constraints;
• markets with recurring injectable shortages.

Revenue durability depends on volume contracts, supply continuity, and product differentiation. A premium price is more defensible for a ready-to-use bag or low-volume concentrated product than for a conventional vial containing the same concentration as multiple generic competitors.

What geographic coverage is available for esmolol products?

The United States is governed primarily by FDA approval, ANDA requirements, Orange Book records, and hospital procurement. European commercialization generally requires a marketing authorization under national or centralized procedures, depending on the product and strategy. Other jurisdictions may accept abbreviated applications but apply different requirements for reference-product selection, stability, packaging, and local manufacturing.

A global excipient strategy should account for:

• permitted excipient limits;
• pharmacopoeial standards;
• local container requirements;
• cold-chain or ambient-storage expectations;
• language-specific concentration labeling;
• country-specific hospital procurement;
• registration of manufacturing sites;
• local shortage and supply obligations.

A formulation optimized for U.S. premix contracts may not be the best product for markets where vials and pharmacy dilution remain standard.

Key Takeaways

• Brevibloc’s molecule and original exclusivity are expired; current opportunity is formulation and supply-chain driven.
• The highest-value excipient strategy is a stable, preservative-free aqueous system with validated pH, osmolality, and container compatibility.
• Ready-to-use bags, low-volume vials, concentrated presentations, and pediatric-compatible packaging offer the clearest commercial differentiation.
• Formulation patents require comparative evidence showing unexpected stability, impurity, compatibility, or manufacturing advantages.
• Generic entry risk is high, while biosimilar risk is not applicable because esmolol is a small molecule.
• Hospital contracts, fill-finish capacity, device compatibility, and shortage resilience may determine commercial value more than patent ownership.
• A conventional esmolol vial is likely to face price erosion. A workflow-oriented product has better pricing and licensing potential.

FAQs

Can esmolol hydrochloride be formulated without sodium chloride?

Yes. A product can use another tonicity and buffering strategy if it meets stability, sterility, osmolality, compatibility, and regulatory requirements. The formulation must be evaluated against the reference product if an ANDA is intended.

Is a high-concentration esmolol product patentable?

Potentially, but concentration alone is unlikely to provide strong protection. Patentability would be stronger if the concentration produced unexpected stability, reduced impurities, improved device performance, or enabled a clinically meaningful low-volume administration format.

Are esmolol injection products subject to biosimilar competition?

No. Esmolol hydrochloride is a chemically synthesized small molecule. Competitors generally use generic-drug pathways rather than the biosimilar pathway.

What is the best commercial package for a new esmolol product?

A ready-to-use, preservative-free, single-dose bag or syringe-compatible presentation has the strongest workflow proposition. A concentrated vial can complement the portfolio where fluid restriction is important.

Can excipient selection support a 505(b)(2) strategy?

Yes, if the product contains meaningful formulation or presentation differences that cannot be supported through a standard ANDA. The sponsor would need to establish the regulatory basis, product-specific safety, quality, and labeling rationale.

References

1. U.S. Food and Drug Administration. (n.d.). Brevibloc (esmolol hydrochloride) injection prescribing information. FDA-approved labeling.

2. National Library of Medicine. (n.d.). DailyMed: Esmolol hydrochloride injection. DailyMed.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.

4. U.S. Food and Drug Administration. (1999). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. FDA.

5. U.S. Food and Drug Administration. (2008). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice. FDA.